23 Feb MEDIPOST
Antonio Lee, Ph.D., Head of Global Operations & Corporate Development
Oct. 8 | 3:30pm | FLW Ballroom F
Seoul, Korea
(KOSDAQ 078160)
MEDIPOST is headquartered in South Korea, with its wholly-owned subsidiaries in the U.S. (MEDIPOST Inc.) and Japan (EVASTEM Co., Ltd.), as well as a stake-holding at a CDMO in Ontario (OmniaBio Inc.), Canada. MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs with hyaluronic acid hydrogel composite administered surgically) for knee osteoarthritis (Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit) To date, over 30,000 patients have been treated with CARTISTEM® in Korea with an excellent long-term safety and efficacy profile. CARTISTEM® is currently under Phase III pivotal trial in Japan and the Phase III pivotal trial in the U.S. is expected to start in 2026.
MEDIPOST’s other allogeneic cell therapeutics pipeline includes clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD).
